Mayo Clinic and Thermo Fisher Scientific form Precure, LLC to spot early biological warning signs of disease

Groundbreaking initiative will produce data at the cutting edge of medicine, helping convert subtle early biological signals into fresh opportunities for prevention, diagnosis, and treatment

Mayo Clinic announced the formation of Precure, LLC, alongside founding partner Thermo Fisher Scientific, described as the global leader in serving science, with the goal of changing how the life sciences field understands the biological shifts that occur as people transition from health to disease.

Through what stands as one of the largest human multi-omics data generation projects undertaken to date, Precure, LLC will build one of the world’s leading biomedical datasets, bringing together proteomic, genomic, and longitudinal clinical data to help researchers spot early biological markers of disease and establish a foundation for fresh discoveries in disease biology, diagnostics, and treatment.

A great many diseases begin their biological development years before symptoms prompt a clinical diagnosis. By tracking molecular and clinical data together over extended periods, Precure, LLC could help researchers gain deeper insight into these early shifts, speed drug development, and create fresh pathways toward earlier diagnosis, intervention, and more personalized treatment across conditions ranging from cancer to cardiometabolic disease, neurological disorders, and immune-mediated illness.

The venture will pool molecular data drawn from one million biospecimens, tied to longitudinal clinical records gathered across several years, merging genomic and proteomic data with Mayo Clinic’s clinical expertise and information within a tightly standardized framework. Advanced artificial intelligence and large-scale data analytics will be central to uncovering patterns across these intricate datasets and converting them into practical, actionable insight. Mayo Clinic will hold majority ownership of the new venture, with Thermo Fisher participating as a minority stakeholder.

Gianrico Farrugia, M.D., president and CEO of Mayo Clinic, said the organization remains focused on transforming patient care through innovation. He said tapping into the full potential of multi-omics data could help the venture understand disease before symptoms surface, speeding discoveries that could lead to earlier diagnoses, more precisely targeted treatments, and improved outcomes for patients.

The two organizations bring complementary strengths to the partnership, aimed at generating the molecular and clinical data needed to accelerate discovery and turn fresh insight into gains in patient care:

• Mayo Clinic pairs top-tier clinical and research leadership with advanced AI and data science tools, an extensive biospecimen collection, and longitudinal de-identified clinical records to speed discovery and convert insight into patient benefit.
• Thermo Fisher contributes leading proteomics expertise and technology, including its Olink™ Explore HT proteomics platform along with Thermo Scientific Orbitrap Mass Spectrometry systems, kits, and reagents, to help construct the venture’s multi-omics infrastructure.

Marc Casper, chairman and CEO of Thermo Fisher Scientific, said the new venture has the potential to fundamentally change how multi-omics data is generated and put to use in improving human health. He said pairing Thermo Fisher’s strength in scientific technology with Mayo Clinic’s leadership in clinical care, research, and innovation opens new possibilities at a scale not previously achieved, for detecting disease earlier, speeding drug development, and enabling more precise treatments.

Precure, LLC works alongside Precure Research, Mayo Clinic’s investigator-led scientific program dedicated to understanding the biological changes that occur as people shift from health toward disease. Precure Research pushes forward the science of identifying and interpreting early disease signals, while Precure, LLC supplies the scale, infrastructure, and partnerships required to generate molecular data at a population level and help turn discoveries into new diagnostics, treatments, and other healthcare tools. Mayo Clinic provides the route to validate these discoveries and ultimately carry meaningful advances into patient care.

Mayo Clinic’s role in Precure, LLC is designed to support its nonprofit mission, with any financial returns reinvested into its ongoing work in patient care, research, and education.

---

---

Related Topics and Keywords

biopharma news, covid, disease, Mayo Clinic, Thermo Fisher, Thermo Fisher Scientific, vaccine, vacine